Solar Capital Stock Earnings Reports

Key points for investors:

- Q1 2026 financials: Net investment income (NII) of $0.33 per share, net income of $0.31 per share. NAV was $18.16 per share at 3/31/2026 (down 0.5% sequentially, flat YoY). Net income for the quarter equates to ~7% annualized ROE. Board declared a quarterly distribution of $0.31 per share payable 6/26/2026.

- Portfolio size and composition: Comprehensive portfolio of ~$3.2 billion at quarter end; on-balance-sheet portfolio fair value ~ $2.1 billion across ~99 portfolio companies. ~85% of portfolio fair value is senior secured specialty finance loans; 94.5% of the comprehensive portfolio is first-lien senior secured loans. Software exposure remains minimal (~2% of fair value).

- Credit quality and performance: 100% of investments at cost were performing; zero nonaccruals. Watch list was low at 2.2%. Weighted average asset-level yield ~11.1% (down vs prior quarter, reflecting rate lag and lower one-time fees).

- Activity and liquidity: Q1 originations $242M; repayments $360M (net repayments ~$180M). Available capital (including SSLP and specialty finance facility capacity) > $900M. Revolving commitments increased to $720M post-quarter. Debt outstanding ~$1.1B; net debt-to-equity 1.14x (within target 0.9x–1.25x). One unsecured note maturity of $75M in Dec 2026.

- Business actions and alignment: Board approved a permanent reduction in performance-based incentive fee from 20% to 17.5%. Board also authorized a one-year extension of the $50M stock repurchase program. Management owns >8% of the company.

- Strategy and initiatives: Firm emphasizes collateral-based specialty finance (asset-based lending, equipment finance, life sciences, cash-flow lending focused on healthcare/sponsor finance). Management is expanding origination teams, pursuing sourcing partnerships (including a recent arrangement with a large U.S. commercial bank for ABL deals), evaluating portfolio and business acquisitions, and expects ABL and life-science churn to normalize over the next 12–24 months to help rebuild fee income. An AI investment committee was formed to assess AI risk across portfolio companies and to implement AI tools internally for underwriting and ops.

- Outlook: Management expects to preserve capital and take an opportunistic stance in dislocations. They believe earnings can recover toward historical levels (management referenced prior ~$0.40 NII per share) over the medium term via portfolio growth, increased ABL/Life Sciences activity, and nonrecurring fee churn. The firm remains conservative on underwriting and emphasizes downside protection.